Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

459 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
Pond GR, Bellmunt J, Fougeray R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD, Agarwal N, Necchi A, Sonpavde G. Pond GR, et al. Among authors: necchi a. Clin Genitourin Cancer. 2013 Dec;11(4):495-500. doi: 10.1016/j.clgc.2013.04.025. Epub 2013 Jun 22. Clin Genitourin Cancer. 2013. PMID: 23800847
Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes.
Necchi A, Nicolai N, Mariani L, Lo Vullo S, Giannatempo P, Raggi D, Farè E, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Milani A, Gianni AM, Salvioni R. Necchi A, et al. Clin Genitourin Cancer. 2014 Feb;12(1):63-69.e1. doi: 10.1016/j.clgc.2013.07.005. Epub 2013 Oct 23. Clin Genitourin Cancer. 2014. PMID: 24161525 Clinical Trial.
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G. Pond GR, et al. Among authors: necchi a. BJU Int. 2014 May;113(5b):E137-43. doi: 10.1111/bju.12564. BJU Int. 2014. PMID: 24219029
Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy.
Pond GR, Di Lorenzo G, Necchi A, Eigl BJ, Kolinsky MP, Chacko RT, Dorff TB, Harshman LC, Milowsky MI, Lee RJ, Galsky MD, Federico P, Bolger G, DeShazo M, Mehta A, Goyal J, Sonpavde G. Pond GR, et al. Among authors: necchi a. Urol Oncol. 2014 May;32(4):501-8. doi: 10.1016/j.urolonc.2013.10.007. Epub 2013 Dec 12. Urol Oncol. 2014. PMID: 24332646
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
Necchi A, Mariani L, Giannatempo P, Raggi D, Farè E, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Pizzocaro G, De Braud FG, Gianni AM, Salvioni R. Necchi A, et al. Clin Genitourin Cancer. 2014 Jun;12(3):203-209.e1. doi: 10.1016/j.clgc.2013.11.022. Epub 2013 Nov 21. Clin Genitourin Cancer. 2014. PMID: 24394493
Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma.
Giannatempo P, Alessi A, Miceli R, Raggi D, Farè E, Nicolai N, Serafini G, Padovano B, Piva L, Biasoni D, Torelli T, Catanzaro M, Stagni S, Maffezzini M, Mariani L, Gianni AM, Sonpavde G, Salvioni R, Necchi A, Crippa F. Giannatempo P, et al. Among authors: necchi a. Clin Genitourin Cancer. 2014 Dec;12(6):433-9. doi: 10.1016/j.clgc.2014.03.007. Epub 2014 Mar 28. Clin Genitourin Cancer. 2014. PMID: 24787972
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design.
Pond GR, Bellmunt J, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Sonpavde G. Pond GR, et al. Among authors: necchi a. Clin Genitourin Cancer. 2015 Feb;13(1):71-9. doi: 10.1016/j.clgc.2014.06.004. Epub 2014 Jun 9. Clin Genitourin Cancer. 2015. PMID: 24993933
Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.
Sonpavde G, Bellmunt J, Rosenberg JE, Regazzi AM, Bajorin DF, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Pond GR. Sonpavde G, et al. Among authors: necchi a. Clin Genitourin Cancer. 2014 Dec;12(6):395-8. doi: 10.1016/j.clgc.2014.03.016. Epub 2014 Jun 10. Clin Genitourin Cancer. 2014. PMID: 25035282 Review. No abstract available.
459 results